Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Recurrent Burkitt Lymphoma: early-phase trial registry

2 of 5 indexed Recurrent Burkitt Lymphoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

Jump to open trials → Trial finder

5 US clinical trials · 2 currently recruiting · #3,391 of 28,707 conditions by registered trial count

Recurrent Burkitt Lymphoma: 5 US clinical trials tracked, 2 recruiting.

Recurrent Burkitt Lymphoma is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 2 of these trials.

Enrollment posture brief

Registry condition recurrent-burkitt-lymphoma

OPEN 2 | RECR 40% | LATE 0 | EARLY 5 | RANK #3391 | SPON 2

Volume-matched condition peers

Nearest open-share peer: Achondroplasia (40% recruiting · 10 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Recurrent Burkitt Lympho (th…40%
Open-enrollment share among volume-matched conditions near Recurrent Burkitt Lymphoma

Recurrent Burkitt Lymphoma lists 2 open slots (40% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Recurrent Burkitt Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Recurrent Burkitt Lymphoma is recruiting below its size-band peers.

    2 of 5 indexed trials (40%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Recurrent Burkitt Lymphoma research.

    M.D. Anderson Cancer Center accounts for 2 of 5 trials (40%). 4 distinct sponsors appear on at least one study for this condition label.

  3. Most Recurrent Burkitt Lymphoma trials plan to enrol fewer than 100 people.

    Median target enrolment is 36 among the 5 trials that report a genuine target (sentinel values excluded). 4 of those (80%) plan for fewer than 100 participants.

  4. Recurrent Burkitt Lymphoma research is mostly interventional.

    5 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 14Phase 21

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 1

Top Sponsors

M.D. Anderson Cancer Center 2 trials
Beth Christian 1 trials
David Bond, MD 1 trials
AIDS Malignancy Consortium 1 trials

Named interventions

Most-linked intervention names on Recurrent Burkitt Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Cytarabine Drug
2 trials
Lenalidomide Drug
2 trials
Dexamethasone Drug
2 trials
Etoposide Drug
2 trials
Laboratory Biomarker Analysis Other
2 trials
Cyclophosphamide Drug
2 trials
Clofarabine Drug
1 trials
Autologous Hematopoietic Stem Cell Transplantation Procedure
1 trials

US sites by state

Facility locations filed on Recurrent Burkitt Lymphoma trials. A trial with sites in several states counts in each.

Texas 2 trials
Ohio 2 trials
Georgia 2 trials
New York 1 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Recurrent Burkitt Lymphoma page

5 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Burkitt Lymphoma condition card totals 5 registered trials; most-linked intervention Cytarabine; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.